PSME3-Interacting Protein: A Promising Drug Target and Biomarker

Target Name: PSME3IP1

NCBI ID: G80011

PSME3IP1

PSME3-Interacting Protein: A Promising Drug Target and Biomarker

Protein-protein interactions (PPIs) play a crucial role in cellular signaling and are a common mechanism for many diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. The protein PSME3-interacting protein (PSME3) is a key player in the regulation of mitochondrial function and energy metabolism, and its dysfunction has been implicated in the development and progression of various diseases. In this article, we will explore PSME3 as a drug target and its potential as a biomarker for disease diagnosis and progression.

PSME3: Structure, Functions, and Interactions

PSME3, also known as mitofusin-3 (Mf3), is a protein that belongs to the family of transmembrane proteins known as the mitofusin family. It is expressed in various tissues and is involved in various cellular processes, including mitochondrial import and export, protein synthesis, and cellular signaling.

PSME3 functions as a protein kinase that regulates mitochondrial protein import, specifically the import of the protein Myosin regulatory protein (Mycp) into the mitochondria. Mycp is a key regulator of mitochondrial function and is involved in the formation of mitochondrial derived vesicles, which are involved in the transport of various cellular organelles to the mitochondria.

In addition to its role in mitochondrial function, PSME3 is also involved in the regulation of cellular signaling. It has been shown to play a role in the regulation of cell proliferation, differentiation, and survival. For example, PSME3 has been shown to promote the growth and survival of various cancer cell lines, and its inhibition has been shown to inhibit the growth and survival of cancer cells.

PSME3 Interactions: Implications for Disease

The dysfunction of PSME3 has been implicated in the development and progression of various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

In cancer, PSME3 has been shown to promote the growth and survival of various cancer cell lines, making it a potential drug target for cancer treatment. For example, PSME3 has been shown to promote the growth and survival of breast cancer cells, and its inhibition has been shown to inhibit the growth and survival of these cells.

In neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease, PSME3 has been shown to play a role in the regulation of mitochondrial function and energy metabolism. Its dysfunction has been implicated in the development and progression of these diseases. For example, PSME3 has been shown to contribute to the neurotoxicity of various neurodegenerative drugs, and its inhibition has been shown to protect against neurotoxicity in these drugs.

In autoimmune disorders, PSME3 has been shown to play a role in the regulation of immune cell function. Its dysfunction has been implicated in the development and progression of these disorders. For example, PSME3 has been shown to contribute to the development of autoimmune diseases, and its inhibition has been shown to protect against the development of these diseases.

PSME3 as a Biomarker: Potential Applications

PSME3 has the potential to serve as a biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its dysfunction has been implicated in the development and progression of these diseases, and its inhibition has been shown to have potential therapeutic applications.

In cancer, PSME3 inhibition has been shown to inhibit the growth and survival of various cancer cell lines, making it a potential drug target for cancer treatment. For example, PSME3 has been shown to inhibit the growth and

Protein Name: Proteasome Activator Subunit 3 Interacting Protein 1

Functions: Promotes the association of the proteasome activator complex subunit PSME3 with the 20S proteasome and regulates its activity. Inhibits PSME3-mediated degradation of some proteasome substrates, probably by affecting their diffusion rate into the catalytic chamber of the proteasome. Also inhibits the interaction of PSME3 with COIL, inhibits accumulation of PSME3 in Cajal bodies and positively regulates the number of Cajal bodies in the nucleus

The "PSME3IP1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PSME3IP1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets